graft versus host disease gvhd market insight

DelveInsight’s ‘Graft Versus Host Disease (GvHD) - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the GvHD, historical and forecasted epidemiology as well as the GvHD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The GvHD market report provides current treatment practices, emerging drugs, GvHD market share of the individual therapies, current and forecasted GvHD market size from 2018 to 2030 segmented by seven major markets. The Report also covers current GvHD treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Graft Versus Host Disease Treatment Market

The Graft Versus Host Disease (GVHD) Treatment Market encompasses a rapidly evolving landscape of therapeutic interventions aimed at addressing the intricate challenges posed by this complex immune-mediated disorder. GVHD occurs when transplanted donor cells recognize the recipient's tissues as foreign and initiate an immune response, leading to potentially severe organ damage. The DelveInsight’s Graft Versus Host Disease market report gives a thorough understanding of the Graft Versus Host Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Graft Versus Host Disease Diagnosis

The Graft Versus Host Disease diagnosis is based wholly on clinical criteria that can be established by biopsy of one of the three target organs. Additionally, laboratory data and/or imaging studies are also useful tests in the diagnostic approach to Graft Versus Host Disease. This segment of the report covers the detailed diagnostic methods or tests for Graft Versus Host Disease.

Graft Versus Host Disease Treatment

Graft Versus Host Disease Treatment is grounded on drugs that reduce the body’s immune response and reduce T cells' number. The current hallmark of treatment for Graft Versus Host Disease is Immunosuppressant medications. These include both corticosteroid drugs and more advanced medications and techniques that decrease the immune response. It covers the details of conventional and current medical therapies available in the Graft Versus Host Disease market for the treatment of the condition. It also provides Graft Versus Host Disease treatment algorithms and guidelines in the United States, Europe, and Japan.

Graft Versus Host Disease Market Dynamics

The Graft versus Host Disease market dynamics is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, Companies like CSL Behring [CSL 964 Alpha-1 antitrypsin (AAT)], MaaT Pharma [MaaT013 (FMT)], and others are involved in the development of Phase III drugs. Apart from this, Phase II drugs are being developed by Regimmune Corporation (RGI-2001) and several others.

Graft Versus Host Disease Market Size

“The Graft versus Host Disease market size in the 7MM is expected to grow at a significant CAGR for the study period (2018-2030). According to the estimates, the United States had the highest Graft versus Host Disease market size in 2019, owing to the higher patient pool and higher treatment costs”

Graft Versus Host Disease Epidemiology 

The Graft Versus Host Disease epidemiology section provides insights about the historical and current Graft Versus Host Disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Graft Versus Host Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Graft Versus Host Disease epidemiology scenarios in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018-2030.

Country Wise- Graft Versus Host Disease Epidemiology

The epidemiology segment also provides the Graft Versus Host Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Graft Versus Host Disease Drug Chapters

The drug chapter segment of the Graft Versus Host Disease report encloses the detailed analysis of Graft Versus Host Disease marketed drugs and late-stage (Phase-III and Phase-II) Graft Versus Host Disease pipeline drugs. It also helps to understand the Graft Versus Host Disease clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Graft Versus Host Disease Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Graft Versus Host Disease treatment.

Graft Versus Host Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Graft Versus Host Disease treatment.

Graft Versus Host Disease Market Outlook

The Graft Versus Host Disease market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%. According to the estimates, the highest market size of GVHD is accessed in the United States followed by Japan and Germany, in 2020.

The United States Market Outlook

In the United States, the total Graft Versus Host Disease market size of GvHD is expected to increase at a CAGR of 17.9% during the study period (2018–2030).

EU-5 Countries: Market Outlook

In EU-5, the total market size of GvHD is expected to increase at a CAGR of 15.5% during the study period (2018–2030).

Japan Market Outlook

The total market size of GvHD in Japan is estimated to rise at a CAGR of 5.6%, during the study period (2018–2030).

Graft Versus Host Disease Drugs and Companies

• IMBRUVICA (ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen
• JAKAFI (ruxolitinib): Incyte Corporation
• ORENCIA (abatacept): Bristol Mayers Squibb
• REZUROCK (belumosudil): Kadmon Corporation (Subsidiary of Sanofi)

Graft Versus Host Disease Drugs Uptake

This section focuses on the rate of uptake of the potential Graft Versus Host Disease drugs recently launched in the Graft Versus Host Disease market or expected to be launched in the market during the study period 2018-2030. The analysis covers Graft Versus Host Disease market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Graft Versus Host Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Graft Versus Host Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Graft Versus Host Disease Pipeline Development Activities

The Graft Versus Host Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Graft Versus Host Disease companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Graft Versus Host Disease report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Graft Versus Host Disease emerging therapies.

Reimbursement Scenario in Graft Versus Host Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the GvHD domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or GvHD market trend. This will support the clients in potential upcoming novel treatment by identifying the over GvHD scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the GvHD Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of GvHD, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight has been provided into the GvHD epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for GvHD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of GvHD market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global GvHD market.

Report Highlights

• In the coming years, GvHD market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence GvHD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for GvHD.
• Our in-depth analysis of the pipeline assets across different stages of development different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the over GvHD scenario of the research and development activities.

GVHD Report Insights

• Patient Population
• Therapeutic Approaches
• GvHD Pipeline Analysis
• GvHD Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

GVHD Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• GVHD Epidemiology Segmentation
• Highly Analyzed Market
• Drugs Uptake

GVHD Report Assessment

• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the GvHD Market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the GvHD total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest GvHD market size during the study period (2018–2030)?
• At what CAGR, the GvHD market is expected to grow in the 7MM during the study period (2018–2030)?
• What would be the GvHD market outlook across the 7MM during the study period (2018–2030)?
• What would be the GvHD market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
• GvHD patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the GvHD market?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the GvHD?
• What is the historical GvHD patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What would be the forecasted patient pool of GvHD in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GvHD?
• Out of GVHD the 7MM countries, which country would have the highest prevalent population of GVHD during the study period (2018–2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of GvHD?

Current Treatment Scenario and Emerging Therapies:

• What are the current options for the treatment of GvHD?
• What are the current treatment guidelines for the treatment of GVHD in the US, Europe and Japan?
• How many companies are developing therapies for the treatment of GvHD?
• How many therapies are developed by each company for the treatment of GvHD?
• How many emerging therapies are in mid stage, and late stage of development for the treatment of GvHD?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GvHD therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for GvHD and their status?
• What are the key designations that have been granted for the emerging therapies for GvHD?
• What is the global historical and forecasted market of GvHD?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the GvHD market.
• To understand the future market competition in the GvHD market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for GvHD in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for GvHD market.
• To understand the future market competition in the GvHD market.